Recomp Stack
Recomposition support stack
Also called body recomposition stack, recomposition protocol, lean mass stack
A phased 16-week peptide stack covering repair, GH axis, sleep and focus. Ten sticks a week, not thirty.
Combination evidence: Preclinical
Where every number on this page comes from
Each quantity carries one of these five labels. They are not interchangeable, and the difference between the first and the last is the difference between a regulated finding and a rumour with a number attached.
- FDA labelling
- This figure appears in FDA-approved product labelling for an approved indication. It is the strongest warrant on this site.
- Published study arm
- This figure is the quantity administered in a named arm of the linked study. It describes what was studied, not what is advised.
- Clinical guideline
- This figure appears in published clinical or professional guidance.
- Manufacturer protocol
- This figure comes from a manufacturer or investigator document rather than from peer-reviewed literature.
- Community practice — no trial
- No clinical trial has tested this figure. It reflects what is commonly reported in practice and carries no evidentiary weight. It is shown because it is what circulates, and because showing it with this label is more useful than pretending it does not exist.
The figure most often reported for each compound. Where a compound has no separately sourced figure at this level, its most commonly reported figure is used instead, and the citation beneath it says so.
Duration
16 weeks
2 phases
Administrations
494
about 38/week at peak
Vials required
28
5 compounds
Cost at this plan
$892.00
Pure Health Peptides, list price
Phase by phase
Weeks 1–10 · 10 weeks
Phase 1 — build
Full stack running. Morning repair group and evening sleep group can each be drawn into a single syringe, which is what takes the daily count from double figures down to two.
BPC-157
2 times daily · Subcutaneous
Lowest sourced, per dose
200 mcgCommunity practice — no trial
Lower end of commonly reported per-administration quantities
Most commonly reported, per dose
250 mcgCommunity practice — no trial
Commonly reported per-administration quantity; twice daily gives the 500 mcg daily figure usually quoted
Prepared at 5 mg in 2 mL
Every quantity above is one administration. At 2 times daily, that is 3.50 mg per week.
| Concentration | 2.50 mg/mL | Draw volume | 0.100 mL |
| Pull to (U-100) | 10.0 units | Doses per vial | 20 |
| This phase | 140 administrations | Vials, this phase | 7 |
Why it is here
Included for connective-tissue support under higher training volume.
What is not known
No human efficacy evidence at any quantity.
CJC-1295 / Ipamorelin blend
Once daily, Monday to Friday · Subcutaneous
Lowest sourced, per dose
100 mcgCommunity practice — no trial
Lower end of commonly reported per-administration quantities for a 5/5 mg blend
Most commonly reported, per dose
200 mcgCommunity practice — no trial
Commonly reported per-administration draw from a 5/5 mg blend, delivering roughly 100 mcg of each compound
Prepared at 10 mg in 2 mL
Every quantity above is one administration. At once daily, monday to friday, that is 1.00 mg per week.
| Concentration | 5.00 mg/mL | Draw volume | 0.040 mL |
| Pull to (U-100) | 4.0 units | Doses per vial | 21 |
| This phase | 50 administrations | Vials, this phase | 3 |
Shelf life, not volume, is what limits this vial. It holds enough for more administrations than you can use inside roughly 30 days of being reconstituted, so the vial count above is driven by that window rather than by the arithmetic. Buying a larger vial would make this worse, not cheaper.
Why it is here
Evening GH-axis pairing, timed to the first deep-sleep block.
What is not known
Mechanistically coherent, clinically untested. See the dedicated protocol page.
AOD-9604
Once daily · Subcutaneous
Most commonly reported, per dose
300 mcgCommunity practice — no trial
Commonly reported morning quantity
Prepared at 5 mg in 2 mL
Every quantity above is one administration. At once daily, that is 2.10 mg per week.
| Concentration | 2.50 mg/mL | Draw volume | 0.120 mL |
| Pull to (U-100) | 12.0 units | Doses per vial | 16 |
| This phase | 70 administrations | Vials, this phase | 5 |
Why it is here
A modified fragment of the growth-hormone molecule, included for its reported effect on fat metabolism.
What is not known
The sponsor's human obesity programme did not produce a marketed product. That is a meaningful negative signal and is rarely mentioned alongside this compound.
GHK-Cu
Once daily, Monday to Friday · Subcutaneous
Most commonly reported, per dose
2 mgCommunity practice — no trial
Commonly reported injected quantity
Prepared at 50 mg in 5 mL
Every quantity above is one administration. At once daily, monday to friday, that is 10.00 mg per week.
| Concentration | 10.00 mg/mL | Draw volume | 0.200 mL |
| Pull to (U-100) | 20.0 units | Doses per vial | 21 |
| This phase | 50 administrations | Vials, this phase | 3 |
Shelf life, not volume, is what limits this vial. It holds enough for more administrations than you can use inside roughly 30 days of being reconstituted, so the vial count above is driven by that window rather than by the arithmetic. Buying a larger vial would make this worse, not cheaper.
Why it is here
Copper tripeptide, included for skin and connective-tissue support.
What is not known
The real human evidence for GHK-Cu is topical and dermatological. Injected use is a different route with a different exposure profile and is not what was studied.
DSIP
Once daily · Subcutaneous
Most commonly reported, per dose
100 mcgCommunity practice — no trial
Commonly reported nightly quantity
Prepared at 5 mg in 2 mL
Every quantity above is one administration. At once daily, that is 0.70 mg per week.
| Concentration | 2.50 mg/mL | Draw volume | 0.040 mL |
| Pull to (U-100) | 4.0 units | Doses per vial | 30 |
| This phase | 70 administrations | Vials, this phase | 3 |
Shelf life, not volume, is what limits this vial. It holds enough for more administrations than you can use inside roughly 30 days of being reconstituted, so the vial count above is driven by that window rather than by the arithmetic. Buying a larger vial would make this worse, not cheaper.
Why it is here
Included for sleep depth alongside the evening GH pairing.
What is not known
The delta-sleep literature is old, small, and has not been replicated with modern sleep staging.
Weeks 11–16 · 6 weeks
Phase 2 — hold
The metabolic components come out. Repair, sleep and GH-axis support continue at reduced intensity. Fewer compounds, lower cost, and a cleaner read on what is actually doing anything.
BPC-157
Once daily · Subcutaneous
Most commonly reported, per dose
250 mcgCommunity practice — no trial
Commonly reported per-administration quantity at the reduced once-daily frequency
Prepared at 5 mg in 2 mL
Every quantity above is one administration. At once daily, that is 1.75 mg per week.
| Concentration | 2.50 mg/mL | Draw volume | 0.100 mL |
| Pull to (U-100) | 10.0 units | Doses per vial | 20 |
| This phase | 42 administrations | Vials, this phase | 3 |
Why it is here
Reduced to once daily.
What is not known
No human efficacy evidence at any quantity.
CJC-1295 / Ipamorelin blend
Once daily, Monday to Friday · Subcutaneous
Most commonly reported, per dose
200 mcgCommunity practice — no trial
Commonly reported per-administration draw from a 5/5 mg blend, delivering roughly 100 mcg of each compound
Prepared at 10 mg in 2 mL
Every quantity above is one administration. At once daily, monday to friday, that is 1.00 mg per week.
| Concentration | 5.00 mg/mL | Draw volume | 0.040 mL |
| Pull to (U-100) | 4.0 units | Doses per vial | 21 |
| This phase | 30 administrations | Vials, this phase | 2 |
Shelf life, not volume, is what limits this vial. It holds enough for more administrations than you can use inside roughly 30 days of being reconstituted, so the vial count above is driven by that window rather than by the arithmetic. Buying a larger vial would make this worse, not cheaper.
Why it is here
Continues unchanged.
What is not known
See the dedicated protocol page.
DSIP
Once daily · Subcutaneous
Most commonly reported, per dose
100 mcgCommunity practice — no trial
Commonly reported nightly quantity
Prepared at 5 mg in 2 mL
Every quantity above is one administration. At once daily, that is 0.70 mg per week.
| Concentration | 2.50 mg/mL | Draw volume | 0.040 mL |
| Pull to (U-100) | 4.0 units | Doses per vial | 30 |
| This phase | 42 administrations | Vials, this phase | 2 |
Shelf life, not volume, is what limits this vial. It holds enough for more administrations than you can use inside roughly 30 days of being reconstituted, so the vial count above is driven by that window rather than by the arithmetic. Buying a larger vial would make this worse, not cheaper.
Why it is here
Continues unchanged.
What is not known
As above.
What you would need to buy
Vial counts are computed by simulating consumption, not by dividing total milligrams. Those two disagree whenever a vial cannot be finished, which is most of the time, and dividing under-buys.
| Compound | Vial | Administrations | Total material | Vials |
|---|---|---|---|---|
| BPC-157Phase 1 — build · Phase 2 — hold | 5 mg | 182 | 45.50 mg | 10 |
| CJC-1295 / Ipamorelin blendPhase 1 — build · Phase 2 — hold | 10 mg | 80 | 16.00 mg | 5 |
| AOD-9604Phase 1 — build | 5 mg | 70 | 21.00 mg | 5 |
| GHK-CuPhase 1 — build | 50 mg | 50 | 100.00 mg | 3 |
| DSIPPhase 1 — build · Phase 2 — hold | 5 mg | 112 | 11.20 mg | 5 |
| Total | 494 | 28 | ||
What it would cost
List prices from each vendor’s own product pages, with the date each figure was read. Quantity tiers are applied where a vendor publishes them.
Loti Labs
Prices as of 2026-08-24
$1,559.38
$13.92/day · $423.82/month
| BPC-157BPC-157 5mg · 5 mg$9.00/mg listed · $9.89/mg after what expires unused | 10 × $44.99 | $449.90 |
| CJC-1295 / Ipamorelin blendCJC-1295 (no DAC) 5mg / Ipamorelin 5mg (blend) · 10 mg$8.55/mg listed · $26.72/mg after what expires unused | 5 × $85.49 | $427.45 |
| AOD-9604AOD-9604 5mg · 5 mg$9.50/mg listed · $11.31/mg after what expires unused | 5 × $47.49 | $237.45 |
| GHK-CuGHK-Cu 50mg · 50 mg$0.97/mg listed · $1.45/mg after what expires unused | 3 × $48.49 | $145.47 |
| DSIPDSIP (Delta Sleep Inducing Peptide) 2mg · 2 mg$14.24/mg listed · $17.81/mg after what expires unusedPriced at the 2 mg size rather than the 5 mg this plan assumes, because across the sizes this vendor stocks it works out cheapest for the whole course. Vial count re-simulated at that strength. | 7 × $28.49 | $199.43 |
| Bacteriostatic water10ML Reconstitution Solution · 10 mLThis plan uses 69.0 mL across every reconstitution. 1.0 mL is left over, because bottles do not divide. | 7 × $14.24 | $99.68 |
| Syringes494 administrations, so 494 syringes. None of the vendors priced on this site sells syringes, alcohol pads or a sharps container. They are ordinary pharmacy items in most places and restricted in some. The count below is what the plan requires; where to obtain them is outside what this site can tell you. | 494 × — | Not sold here |
| Total, compounds and water | $1,559.38 | |
Above this vendor's published $99 free-shipping threshold.
We earn nothing from this link. Loti Labs has no affiliate programme.
Pure Health Peptides
Prices as of 2026-08-24
$968.93
$8.65/day · $263.34/month
| BPC-157BPC-157 · 5 mg$4.40/mg listed · $4.84/mg after what expires unusedThis listing is sold in several vial sizes and the figure shown is the cheapest one, so the real price is higher. | 10 × $22.00 | $220.00 |
| CJC-1295 / Ipamorelin blendCJC-1295 (DAC)/IpamorelinThis listing is sold in several vial sizes and the figure shown is the cheapest one, so the real price is higher. The listing does not publish a vial size, so the vial count is the plan's own and may not match what ships. | 5 × $58.00 | $290.00 |
| AOD-9604AOD9604This listing is sold in several vial sizes and the figure shown is the cheapest one, so the real price is higher. The listing does not publish a vial size, so the vial count is the plan's own and may not match what ships. | 5 × $42.00 | $210.00 |
| GHK-CuGHK-CuThis listing is sold in several vial sizes and the figure shown is the cheapest one, so the real price is higher. The listing does not publish a vial size, so the vial count is the plan's own and may not match what ships. | 3 × $29.00 | $87.00 |
| DSIPDSIPThis listing is sold in several vial sizes and the figure shown is the cheapest one, so the real price is higher. The listing does not publish a vial size, so the vial count is the plan's own and may not match what ships. | 5 × $17.00 | $85.00 |
| Bacteriostatic waterBacteriostatic Water · 10 mLThis plan uses 65.0 mL across every reconstitution. 5.0 mL is left over, because bottles do not divide.The only size this vendor sells. Stock was reported as one unit remaining when read. | 7 × $10.99 | $76.93 |
| Syringes494 administrations, so 494 syringes. None of the vendors priced on this site sells syringes, alcohol pads or a sharps container. They are ordinary pharmacy items in most places and restricted in some. The count below is what the plan requires; where to obtain them is outside what this site can tell you. | 494 × — | Not sold here |
| Total, compounds and water | $968.93 | |
Above this vendor's published $175 free-shipping threshold.
We earn nothing from this link. No affiliate programme was found for this vendor.
Peptira
Prices as of 2026-08-25
$1,011.30
$9.03/day · $274.86/month
| BPC-157BPC-157 · 10 mg$4.16/mg listed · $5.49/mg after what expires unusedPriced at the 10 mg size rather than the 5 mg this plan assumes, because across the sizes this vendor stocks it works out cheapest for the whole course. Vial count re-simulated at that strength. | 6 × $41.65 | $249.90 |
| CJC-1295 / Ipamorelin blendPeptira lists this compound only as part of a single-compound vial, which is not what this plan uses. Its cost is not included below. | — | — |
| AOD-9604AOD-9604 · 5 mg$8.33/mg listed · $9.92/mg after what expires unused | 5 × $41.65 | $208.25 |
| GHK-CuGHK-CU RAWThe listing does not publish a vial size, so the vial count is the plan's own and may not match what ships. | 3 × $37.05 | $111.15 |
| DSIPDSIP · 10 mg$7.56/mg listed · $33.77/mg after what expires unusedPriced at the 10 mg size rather than the 5 mg this plan assumes, because across the sizes this vendor stocks it works out cheapest for the whole course. Vial count re-simulated at that strength. | 5 × $75.65 | $378.25 |
| Bacteriostatic waterBAC Water 10ML · 10 mLThis plan uses 47.0 mL across every reconstitution. 3.0 mL is left over, because bottles do not divide. | 5 × $12.75 | $63.75 |
| Syringes494 administrations, so 494 syringes. None of the vendors priced on this site sells syringes, alcohol pads or a sharps container. They are ordinary pharmacy items in most places and restricted in some. The count below is what the plan requires; where to obtain them is outside what this site can tell you. | 494 × — | Not sold here |
| Total, compounds and water | $1,011.30 | |
Above this vendor's published $250 free-shipping threshold.
This total is not comparable. Peptira cannot supply CJC-1295 / Ipamorelin blend, so the figure above covers a smaller basket than the other columns.
Peptira runs an affiliate programme. This site has not applied to it, so no commission is earned on this link today.
List price is not the price anyone pays
What usually goes wrong
Ranked by how often it happens rather than by how serious it sounds.
Running five compounds at once and learning nothing
If everything starts on the same day, no observed change can be attributed to anything. Staggering starts by a week or two costs nothing and is the only way this produces usable information.
Drawing incompatible compounds into one syringe
The water-based peptides here can share a syringe. Anything oil-based cannot, and nothing should be combined without checking. The planner below groups by administration time and flags what must stay separate.
Underestimating the reconstituted shelf life
Reconstituted peptides degrade. Buying a 50 mg vial to use 2 mg a day means the last dose is months old. The supplies planner accounts for this; a spreadsheet usually does not.
Costing the stack from list prices
Vendor list price is almost never the transacted price in this market. The cost model on this site shows list, bulk tier, and an as-of date, and it does not pretend to know what promo code is running this week.
What is worth measuring
Markers that would actually tell you something, and what each one tells you. Nothing here is a requirement, and none of it substitutes for a clinician who knows your history.
| Marker | When | What it tells you |
|---|---|---|
| Body composition, not scale weight | Baseline and every 4 weeks | Recomposition moves two numbers in opposite directions; scale weight hides both. |
| IGF-1 | Baseline and week 8 | The measurable marker for the GH-axis component. |
| Fasting glucose | Baseline and week 8 | GH-axis stimulation raises insulin resistance. |
| Sleep quality | Nightly, subjectively | Two components target it directly and it is the fastest-reading endpoint here. |
Populations this was not studied in
An absence of evidence in a group is not evidence of safety in that group. These are listed because the gap itself is the finding.
- Any human population, for this combination
- Active or historical malignancy
- Pregnancy and breastfeeding
- Anyone under 18
Related protocols
Tesamorelin
2 mg daily, from an approved label, with a 52-week pooled analysis behind it.
Wolverine Stack
The most-searched stack in this category, and the one with the least human evidence behind it.
CJC-1295 + Ipamorelin
The standard evening pairing. Pharmacologically coherent, clinically unproven.
Protocol last reviewed 2026-08-24. Every quantity on this page carries its own source. If you find one that does not, that is a bug and the build should have caught it.